Blue Eye™ Submucosal Injection Agent is a Class II medical device, an injectable solution intended to assist in the endoscopic resection of polyps, adenomas, and other gastrointestinal lesions when needed.
Blue Eye™ provides a helpful lift of the lesion that lasts longer for the endoscopist, and also provides improved visualization of the lesion and underlying tissue.
Blue Eye™ is expected to result in fewer injections, shortened procedure time and better outcomes.
Used since 2019, Blue Eye™ was cleared by FDA in late 2022, and became available for use by U.S. endoscopists in 2023. Some early comments from our physician customers who have used Blue Eye™ are “helpful”, “successful”, “fantastic”, and “less expensive”.
